Retatrutide is a triple gip/glp-1/glucagon receptor agonist with a development status of "phase 3 clinical trials". The Institute rates the strength of its published evidence as moderate. An investigational triple-agonist in late-stage trials, with phase 2 data showing the largest weight reductions yet reported for an incretin therapy.
The distinction that matters most when reading about Retatrutide is between what has been demonstrated and what has been proposed. Mechanistic plausibility is not evidence of effect, and a compound can have a well-characterised receptor interaction while producing no measurable clinical benefit. That gap is where most of the confusion in this space lives.
Where human data exists for Retatrutide, endpoints are frequently surrogate measures rather than outcomes people care about. A change in a biomarker is a reason to run a larger trial, not a reason to conclude the trial would succeed.
The Institute has independently tested 21 Retatrutide samples from 11 companies. 86% met their label claims on purity and content. Measured purity ranged from 58.2% to 99.7%, averaging 94.4%. 2 samples failed verification outright. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
